KEWAUNEE SCIENTIFIC CORP /DE/ — Form 8-K
Filed September 9, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 48/100
What the filing says
Kewaunee Scientific reported Q1 FY2027 (ended July 31, 2026) sales of $66.3M (down 6.7% YoY from $71.1M), net earnings of $1.7M (down 45% from $3.1M), and diluted EPS of $0.58 (down 44% from $1.04). Backlog improved slightly to $169.0M from $165.9M (but down from $205.0M a year prior). The company took a one-time charge to settle long-term incentive awards in cash rather than shares; excluding this, results reflect margin pressure in the Lab Products Group (LPG) due to weak life sciences demand, partially offset by strong International segment margin improvement (net earnings +23.5%, EBITDA +13.9%) driven by favorable project mix. Debt (ex-sale-leaseback) declined $1.2M to $13.8M.
Why this rating
Sales and earnings declines of 6–7% and 44–45% are material to a $70M market-cap firm, signaling near-term weakness. However, backlog remains healthy, International improving, and management emphasizes long-term positioning. Not a going-concern issue, but real operational pressure.
See more from September 9, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.